Background: There is abundant evidence of the comparative efficacy of singlefraction (SF) radiotherapy and multi-fraction (MF) radiotherapy when treating patients with bone metastases. Despite this, previous surveys have shown SF schedules to be underutilised.
Introduction
After lung and liver, the skeletal system is the most common location for metastasis (1) . Skeletal metastases develop in 70-80% of patients with breast or prostate cancer and in up to 40% of patients with advanced stage lung cancer (2) .
Bone metastases can cause significant morbidity. The management of bone metastases depends upon location as well as patient performance status and previous treatment (1) . Therapeutic options include: analgesics, systemic therapy, bisphosphonates and radiotherapy. The purpose of such treatments are to relieve pain and reduce risk of fractures. Treatments can also prevent problems linked with untreated progressive disease such as spinal cord compression (3) .
It has been found that 50% of cancer patients will have palliative radiotherapy during the course of their disease. Palliative radiotherapy has a 50-80% likelihood of overall pain relief (4) . Randomised controlled trials have been carried out comparing single and multiple fractionated (SF and MF) regimes. Even though the findings have shown a comparative efficacy of both single and multiple fractionated schedules, it has been shown single fraction treatments remain underused (5; 6; 7; 8;9) . The aim of this study is to carry out an audit of a number of radiotherapy departments and their current external beam radiotherapy regimes to investigate factors associated with the choice of dose and fractionation in the treatment of bone metastases.
Ethical Issues
Participants and their trusts were assured of their and their trusts anonymity and permission were granted from the managers at each department. Nine departments were contacted which had a partnership with Sheffield Hallam University.
With regards to approval of this study, the Faculty of Health and Wellbeing Research Ethics Committee was consulted, and approval received (10) .
Once permission was gained, an email was sent to the consultants and registrars inviting them to take part.
Materials and Method:
An electronic audit was designed and performed amongst 46 physicians, within 7 hospital trusts. The 7 trusts used were partnered with Sheffield Hallam University as part of their 9 current training sites. This was distributed using Survey Monkey (Survey Monkey Solutions, Dublin, Ireland). An advantage of an electronic audit is that they tend to acquire a greater response compared to postal surveys (11) .
The audit comprised of open and closed questions, 4 hypothetical cases of patients with bone metastases as well as general demographic questions. Population, Exposure and Outcome (PEO) and Population, Intervention, Comparison, Outcome (PICO) research models were used to help shape and define questions.
The hypothetical cases used within the survey were adapted from previous studies to allow comparisons to be made (5; 6; 7;9) . (12) .
Sampling
The sampling method that was used was voluntary convenience sampling.
Consultants and registrars in oncology were invited to participate via email.
Data analysis
The data was analysed using the Statistical Package for Social Sciences (SPSS), version 24. There was a mixture of qualitative and quantitative questions used. The type of variable used established how the data was presented (13) . Quantitative variables would include nominal or ordinal variables which can be presented using graphs to identify any patterns. In this case, the nominal variables were the number of consultants that prescribed a certain fraction for a hypothetical case.
The data was represented using bar graphs (see fig 1 and 2. ) so that comparisons could be made (13) . In that, the radiation dose prescription that each consultant and registrar decided to prescribe were compared for each hypothetical case. The data was also presented in tables 2 and 3, so that cross-tabulation could occur.
As categorical data was produced a chi-square test (x 2 ) performed to test significance between two variables such as factors associated with the choice in fractionation (14) . A P value lower than 0.05 was considered to indicate statistical significance. fractions. The single fraction usually consists of either 6 Gy or 8 Gy (1) .
A systematic review and meta-analysis of the literature, which compared SF radiotherapy to a MF schedule for patients with bone metastases was completed by Sze et al. (8) in which eleven trials involving 3435 patients were identified. The findings had shown that the overall pain relief response rate was 60% for patients that had a SF and 59% for those that had a MF regime of radiotherapy. Confidence intervals were 0.89 to 1 which infers that were no differences in overall pain relief within the treatment schedules. The similarity between the treatment schedules regarding complete pain response implies that SF radiotherapy is as effective as multiple-fractionated radiotherapy, in terms of pain relief. Similar findings were
shown by Arnalot et al. (15) , Chow et al. (16) and Wu et al. (17) .
Strengths of a single fraction
Another advantage of SF treatments was demonstrated by Hartsell et al. (18) . Their results show that the SF schedule had less acute toxicity compared to the MF arm.
This study only included patients with primary breast or prostate cancer which means outcomes may not be the same as other sites. However, Wu et al. (17) compared factors such as pain relief and acute toxicities across different tumour types and found that there was no significant difference in pain relief. Furthermore, the quality of life assessment did not show a difference between the single and multiple fractionation arms.
Hartsell et al. (18) further highlighted that SF radiotherapy offers a major economic advantage of savings in radiotherapy capacity. However, reimbursement and health infrastructure are different in the US than in the UK, making it is difficult to apply these findings to the UK health care setting. Hartsell et al. (18) stated that fewer visits to the hospital would result in lower cost for the patient.
Weaknesses of single fraction
One of the main drawbacks of delivering palliative radiotherapy in a SF is the retreatment rate being higher than a multiple fractionated regime. Chow et al. (16) found that the retreatment rate was 2.6-fold greater in the SF arm, statistically significant (p=0.00001). The reasoning behind this could be due to the radiation oncologists being more willing to retreat patients when they have had a SF due to SF treatments being well within the limits of radiation tolerance (17, 19, 20) .
Another weakness of delivering the 8 Gy in a SF compared to MF schedule is the risk of a pathological fracture in the single fraction arm is greater (16) . Though, the systematic review had shown that there was not a significant difference between the two when they had reviewed 10 trials that had reported pathological fracture rates.
Despite the results not being statistically significant, there was a trend for lower rates in the multiple fractionation arm.
Stereotactic Body Radiotherapy
Stereotactic Body Radiotherapy (SABR) is a technique used to deliver a high dose of radiation to a target in a smaller number of fractions in comparison to conventional radiotherapy. This can provide better local control and longer symptom palliation in the setting of bone pain, compared to conventional radiation therapy. There are certain criteria that need to be met for SBRT treatment such as: well-circumscribed, inoperable lesion (21) . Current published results suggest that we can use singlefraction at up to 20 Gy for relief of acute bone pain (21) .
Studies to show patterns of practice
In spite of the number of randomised controlled trials showing the efficacy of delivering radiotherapy in a single fraction (8; 15; 16; 17) , there is a variation in practice on an international basis as well as differences between centres in the UK. For instance, a study distributed an electronic survey to radiation oncologists to find out their patterns of practice (5) . The findings showed that the most prescribed schedule was 30 Gy in 10# emphasising a gap between evidence and practice. It also looked at the decision factors affecting dose prescription which allowed for comparisons to be made. In that, the oncologists were more likely to prescribe a shorter fractionation regime if the life expectancy of the patient was short.
As mentioned, patterns of practice may vary between radiotherapy centres. A review collated several trials to determine global patterns of practice (22) . It was found that radiation oncologists from the United States (US) and Asia were less likely to deliver radiotherapy in a single fraction (range: 1-15.6% of hypothetical cases) whereas patients in Canada, Australia and from the United Kingdom were more likely to receive a SF (range: 10.9-38.9%). The variation in practice may be due to:
oncologist preference, possibly influenced by reimbursement, patient age and the number of sites of bone metastases (23) . It was concluded that a global reluctance still exists regarding the prescription of a single fraction of radiotherapy over the 20 years they had studied (1993-2013) (22) .
It was found that (24) , the utilisation rate of single-fraction was below 5%
despite the American Society for Radiation Oncology (ASTRO) guidelines, as a result ASTRO published new guidance in 2017 (25) . This was due to new literature that had arisen since 2011 (16) . The results of the chi squared test had shown certain factors to have an influence on the fractionation schedule. Table 2 shows the factors that had a significant relationship between the single fraction and the factors for each case. The results had shown that certain departments are more likely to choose a single fraction. Table 3 shows how many physicians at each department decided to prescribe 8 Gy in 1# for case 1. The physicians from department 9, all decided they would give a single fraction. Whereas, 66% of physicians at department 1 would choose the single fraction. Furthermore, the physicians at department 6 were more likely to choose a multi-fraction regime.
For case 2, table 3, shows that, all of the physicians at department 1 would prescribe 20 Gy in 5#. In comparison to this, all the physicians at department 4 and 5 would deliver radiotherapy in a single fraction. However, department 3,8 and 9 indicated differences within their departments. were: department policy, finance, patient choice and patient age.
Case 1
The results had shown that the majority of consultants and registrars would use a SF (65.2%). This case was modified from a study, (6) to allow comparisons to be made.
In fact, their results had shown that only 12.1% of all respondents recommended SF radiotherapy. This suggests that since 2009, an increased uptake in consultants preferred to use SF radiotherapy. There was a significant relationship between SF radiotherapy and prognosis, x 2 (1, N=46) = 9.58, p= .002. This is comparable to other studies such as: (5) who found that 69.3% of respondents felt that the prognoses of patients are a factor that would influence their decision. It was found that 46% of respondents would choose SF radiotherapy if the patient has a poor prognosis (3) . A study (6) stated that stated that due to the limited survival of palliative patients, the use of SF radiotherapy is recommended, to decrease the time spent in medical appointments Case 1 involved disease at T6-T9. It is not feasible to use SABR to treat extensive multilevel disease that involves the spine (21) . However, a respondent recommended a "SBRT type dose if she has oligometastatic disease".
Another respondent stated that, travelling distance can be a factor, but "other factors selected usually have more of an impact on choice of dose/fractionation". As part of the reasoning from Lutz et al. (25) recommending the use of a SF, it was mentioned that a single 8 Gy fraction provides a none inferior pain relief compared to a MF regime, which can be convenient for patients with a poor prognosis. Patient convenience was an important factor when recommending the fractionation, in 3.4% of patients (5) . This indicates that this is not one of the main factors in determining dose (5) .
Case 2
For case 2, 22 respondents (47.83%) selected delivering a SF schedule whereas, 24 respondents (52.17%) chose a multi-fractionated regime. Indicating differences in the dose prescription when patients have spinal cord compression. A comparable case about spinal cord compression was in a survey distributed in Italy (9) . The results had shown that 30% of respondents would prescribe SF radiotherapy. The low use of SF radiotherapy was attributed to the perceived risk of cord compression and that neuropathic pain requires high doses to alleviate pressure on nerves.
Nakamura et al. (7) included a comparable case within their study and the findings had shown that 79% of respondents would deliver using a multi-fractionated regime.
However, a small sample size reduces reliability in this study.
On the other hand, two respondents noted that "SCORAD trial results" influenced their decision of choosing a SF. Hoskin et al. (26) Case 3 described a hormone-refractory prostate cancer patient, who presented with progression of pain which was found to be osteoblastic lesions in the left shoulder.
The findings had shown that 89.3% of responded would choose SF radiotherapy.
The survey distributed by Fairchild et al. (6) had a comparable case which was also found to have 8 Gy in 1# as the most common regimen. There was a significant relationship between prognosis and delivering a SF as p=0.01. This is because of the limited survival of patients and the importance of decreasing the time invested in hospital appointments (6) .
A respondent chose to deliver a SF schedule but stated the increased likelihood of retreatment due to this. As mentioned, Chow et al. (16) found that the retreatment rate was 2.6-fold greater in the SF arm compared to MF. However, this could be due the radiation oncologists being more willing to retreat patients as the sum of both treatments would be within the limits of radiation tolerance (17) . Jhaveri et al. (21) looked at SABR for bone metastases to investigate the impact of high doses at a target using single or multiple doses. It was found that SBRT can be safe and effective in relieving bone pain from metastatic disease. Current published results have shown that SF-SBRT of up to 20 Gy can be used to relieve bone pain (21) . One of the respondents suggested a dose of 20Gy in 5# and mentioned that it is a resistant disease. However, Jhaveri et al. (21) stated that doses of up to 20Gy can also be used for radioresistant tumour types such as renal cell carcinoma. The implications of this is that, in the future the use of SABR may increase due to the positive findings studies have shown.
Inter-institution differences
As mentioned, certain departments are more likely to deliver SF radiotherapy such as departments 4, 5 and 6 (see table 3 ).
In terms of the frequency of respondents of each departments suggesting SABR for case 4 in a SF, there were 4, 3,2,1 number of respondents from department 1,4,8 and 3 respectively. This could be due to the increased use of SABR within these departments.
Limitations
Limitations include the primary researchers lack of experience in this type of research.
Another limitation was the small sample size. Due to the small absolute sample size (n = 46), the results might not accurately represent the practice of physicians in the UK. Previous studies regarding patterns of practice with patients that have bone metastases have stated the response rate of the health professionals involved in their studies have been low which can affect the validity and reliability of their findings. Magne et al. (3) had a response rate of 15.7% and Nakamura et al.'s (7) study had a response rate of 36%.
Conclusion
This survey has shown that the results tally with recent guideline recommendations (25) . In that, the majority of respondents recommended a SF to treat patients with bone metastases. The factors which had influenced the consultants and registrars to choose a SF schedule were: published evidence, prognosis, performance status and spinal cord-compression. The factors considered the least often were: patient choice, finance, late side effects and department protocol. But, about a third of respondents indicated use of MF regimes. The use of SABR may increase in the future due to studies supporting the its use in a palliative setting for patients with solitary metastases.
